Cabometyx®

Active substance

Cabozatinib

Holder

IPSEN Pharma

Status

Closed

Indication

Advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)- targeted therapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

16/02/2018

Last updated on 13/02/2024